Actively Recruiting
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
Led by Lindenwood University · Updated on 2025-12-12
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
L
Lindenwood University
Lead Sponsor
I
Increnovo LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are examining how different doses of glucosyl-hesperidin (CITRAPEAK) affect exercise performance, recovery, blood flow, cognitive function, mood, sleep, and fuel use in healthy, recreationally active adults aged 18 to 50. This randomized, double-blind, placebo-controlled study aims to understand dose-dependent effects in this population to support cardiovascular and cognitive health improvements. Participants will be randomly assigned to one of three groups: a placebo group receiving a daily 400 mg cellulose supplement; a group receiving 200 mg glucosyl-hesperidin plus 200 mg cellulose daily; or a group receiving 400 mg glucosyl-hesperidin daily. The study lasts 8 weeks, with daily supplement intake monitored through logs. The design includes multiple visits with various assessments, including exercise testing, blood flow measurements, and cognitive evaluations. During the study, participants will undergo tests such as peak VO2 and Wingate anaerobic power assessments, blood flow analysis at multiple times post-supplement intake, and mood and sleep quality questionnaires. Researchers will track adherence via supplementation logs and measure changes in physical and cognitive performance, mood, sleep, and nitric oxide levels. Participation spans the full 8-week supplementation period with evaluations at baseline and week 8.
CONDITIONS
Brief Title
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 to 50 years
- Body mass index between 25.0 and 30.0 kg/m2
- Average study group BMI must remain below 27.0 kg/m2
- Free-living and independent individuals
- In good health without cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal diseases
- Willing to maintain consistent sleep before study visits
- Able and willing to consent and follow study procedures
- Regularly complete at least 180 minutes of moderate to vigorous exercise weekly for the past 6 months
You will not qualify if you...
- Not meeting the exercise requirement of 180 minutes per week for the past 6 months
- History or treatment of heart or cardiovascular disease
- Kidney disease, renal failure, or regular dialysis
- Liver disease or clinically diagnosed hepatic impairment
- Diagnosed Type I or Type II diabetes
- Thyroid disease diagnosis or treatment
- Major psychiatric disorder requiring hospitalization in the past year
- Immune disorders such as HIV/AIDS
- History of cancer except certain localized skin or cervical cancers
- Gastrointestinal tract abnormalities affecting swallowing or digestion
- Neurological conditions or diseases
- Use of statin or hypertension medications
- Current smoking or recent quitting within 6 months
- Use of weight loss drugs or supplements
- Pregnant, lactating, or planning pregnancy
- Known allergies to study products
- History of alcohol or substance abuse within 12 months
- Participation in another research study within 30 days
- Orthopedic limitations preventing fitness participation
- Any condition deemed unsafe or compromising study data by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants consume their assigned supplement daily for 8 weeks to evaluate the effects on exercise performance, recovery, cognitive function, mood, and cardiovascular health.
Multiple visits including baseline and Week 8 assessments with exercise performance tests, blood flow analysis, and cognitive evaluations
Trial Site Locations
Total: 1 location
1
Lindenwood University
Saint Charles, Missouri, United States, 63301
Actively Recruiting
Research Team
A
Anthony M Hagele, MS
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here